RICHARD MULLIN: Open Payments
NPI 1851598668 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$172 in 9 payments from 8 companies in 2025. Trend: 2023 $463 · 2024 $314 · 2025 $172
Food & beverage: $172
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Alkermes, Inc. | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Neurocrine BioSciences, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $16 |
| ABBVIE INC. | 1 | $16 |
Products named: TRINTELLIX, VIVITROL, FANAPT, ABILIFY ASIMTUFII, Leqembi, INGREZZA, CAPLYTA, VRAYLAR.
Industry payments across NY — which companies pay providers there.
